Inclusion Criteria:  Diagnosis of relapsing-remitting or progressive MS. Presence of depressive symptomatology, with HADS scores > 8, confirmed by HDRS scores (clinical interview) > 14. No change of pharmacological treatment in the 3 months before the enrolment. Ability to communicate and to understand tasks. No clinical relapses or use of steroid treatment during the 4 weeks before the enrolment. Provided informed consent for study participation.  Exclusion Criteria:  Severe co-morbidity that would reduce life expectancy to less than one year (i.e. end-stage oncological diseases or severe cardiac dysfunction). Severe neuropsychological impairment evaluated with the MMSE. Psychosis or dissociative disorders. No current psychotherapy treatment Pregnancy.